Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BrightSpire Capital, Inc. Class A Common Stock (NY:BRSP)

5.880 -0.060 (-1.01%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BrightSpire Capital, Inc. Class A Common Stock

< Previous 1 2 Next >
BrightSpire Q2 Earnings Beat 16%
Via The Motley Fool
Topics Earnings
BrightSpire Capital Inc (NYSE:BRSP) Reports Mixed Q2 2025 Earnings with Earnings Beat and Revenue Shortfall
BrightSpire Capital (BRSP) reported mixed Q2 2025 results, beating earnings estimates but missing revenue. Shares rose 2.2% as dividend coverage and risk reduction boosted investor confidence. 
Via Chartmill
Topics Earnings
Earnings Scheduled For July 29, 2025
 
Via Benzinga
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
This Core Scientific Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
 
Via Benzinga
Earnings Scheduled For April 29, 2025
 
Via Benzinga
Earnings Preview For BrightSpire Capital
 
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Earnings Preview For BrightSpire Capital
 
Via Benzinga
BrightSpire Capital Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
BRSP Stock Earnings: BrightSpire Capital Meets EPS, Beats Revenue for Q2 2024
BRSP stock results show that BrightSpire Capital met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BRSP Stock Earnings: BrightSpire Capital Beats EPS, Beats Revenue for Q1 2024
BRSP stock results show that BrightSpire Capital beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
GameStop Posts Downbeat Results, Joins Direct Digital, Forge Global And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Downgrades Flood In For Commercial Real Estate Stocks: Analysts Warn Of 'Rocky Road Ahead'
Bank of America has downgraded six Commercial Real Estate mortgage REITs. Here's why. 
Via Benzinga
Earnings Outlook For BrightSpire Capital
 
Via Benzinga
Looking Into BrightSpire Capital's Return On Capital Employed
 
Via Benzinga
BrightSpire Capital: Q1 Earnings Insights
 
Via Benzinga
Looking Into BrightSpire Capital's Return On Capital Employed
 
Via Benzinga
Earnings Scheduled For February 18, 2025
 
Via Benzinga
US Mortgage Applications Surge As Rates Dip: Is The Industry Moving Out Of The Woods? Plus: Stocks, ETFs To Watch
The latest data from the Mortgage Bankers Association (MBA) revealed a significant uptick in U.S. mortgage applications. 
Via Benzinga
Topics ETFs
These 3 REITs Just Jumped Higher On Earnings Beats
 
Via Benzinga
The Best-Performing Mortgage REITs In 2023
Among real estate investment trusts (REITs), one of the most popular subsectors with investors are mortgage REITs (mREITs). Although mREITs can be extremely volatile, their dividend yields are usually... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
 
Via Benzinga
Earnings Scheduled For October 30, 2023
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter. 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
Novavax, AMC Entertainment And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
A Look Into Real Estate Sector Value Stocks
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.